C
urrent medical therapies for ulcerative colitis (UC), a type of inflammatory bowel disease (IBD) with inflammation confined to the colon, are inadequate to achieve remission in all patients. Mesalamine fails to induce remission in more than 50% of patients, and relapse rates are high even for those who do achieve remission (1) . These patients often must choose between surgery or escalation of medical therapy with corticosteroids, long-term immunosuppressant therapy, or both. Corticosteroids have been associated with increased infection and mortality risks (2) (3) (4) . Immunosuppressant therapy (such as thiopurine or anti-tumor necrosis factor medications) is associated with increased infection and cancer risks (3, (5) (6) (7) (8) (9) (10) (11) (12) (13) , and a significant proportion of patients still does not achieve or maintain remission (5, 14, 15) . These patients are exposed to additional courses of corticosteroids and, sometimes, emergent colectomy, which carries higher morbidity and mortality than elective surgery (16 -19) .
Alternatively, patients with UC can pursue elective colectomy, which involves total proctocolectomy with ileostomy and, often, restorative ileal pouch anal anastomosis. Although quality of life is altered after surgery and up to 40% of patients experience pouchitis (20) , these procedures carry low morbidity and mortality when pursued electively (16, (21) (22) (23) . Two prior studies have suggested that elective colectomy may be associated with a survival benefit in patients with UC and that this benefit may vary by patient age; however, both studies were subject to confounding by indication due to an inability to adjust for disease severity (19, 24) .
Quality of life, morbidity, and mortality are important factors that drive patients' and physicians' treatment decisions (25) . Therefore, clarifying whether elective surgery provides a survival advantage relative to medical therapy for patients with UC is important. In this study, we used U.S. Medicare and Medicaid data to conduct a retrospective cohort study examining whether patients with advanced UC pursuing elective colectomy had improved survival compared with similar patients receiving long-term medical therapy. 
. I-28
sure capture of elective surgeries, surgical codes were required to have been assigned within 24 hours of the admission associated with that surgery, and the patient could not have had an emergency department visit on that day or the day before. Patients who did not meet these criteria were defined as having emergent colectomy.
Cohort Selection
Our goal was to select a cohort of medically treated patients who were as similar as possible to our surgery patients yet did not have elective surgery. Each elective surgery patient was matched with up to 10 medically treated patients with advanced UC on the basis of the time between when they first met criteria for advanced disease and when they had surgery, as described in the next paragraph (Supplement). In addition, the medical therapy patient had to match the surgery patient at the start of follow-up on age (categories shown in Table 1 ), sex, specific immunosuppressant therapy used in the 6 months before the start of follow-up (including corticosteroids), reason for inclusion in the advanced disease cohort, and Medicaid eligibility (as a proxy for low income) (Supplement).
Follow-up for patients in the surgery cohort started on the date of their elective surgery. The time between when they met the advanced disease criteria and when they had surgery was used to match up to 10 medically treated patients (Supplement). Follow-up for patients in the medically treated group began the same number of days after they met the definition of advanced disease as the number of days after which the surgery patient had colectomy. Any patient with advanced UC who had not had surgery before this date was eligible to be a match.
Matched medical therapy patients who had emergent colectomy after the start of follow-up continued to contribute follow-up to the medical therapy cohort in an intention-to-treat manner. If medical therapy patients had elective surgery after the start of follow-up, they were rematched at the time of their elective surgery with an appropriate medical therapy patient and contributed follow-up to both the medical therapy and surgery cohorts from that point forward.
Statistical Analysis
The primary outcome of interest was mortality, which is identifiable in Medicare and Medicaid records by the date of death. Cox regression was used to compute unadjusted and adjusted hazard ratios (HRs) and 95% CIs. To account for the variable number of matches, we used a weighted Cox regression (Supplement). Our primary exposure of interest was treatment strategy (surgery vs. medical therapy). Additional potential confounders were also evaluated in the 180 days before the start of follow-up ( Table 1) . Comorbid conditions were categorized using the combined Romano/ Charlson-Elixhauser comorbidity index (≤1 or ≥2) (32) . Polypharmacy was assessed by counting the number of unique non-IBD medications prescribed using National Drug Code identifiers. Potential confounders were added separately; variables with a greater than 10%
EDITORS' NOTES Context
Ulcerative colitis (UC) can be treated surgically or medically. Whether elective colectomy offers a survival advantage over medical therapy for patients with advanced UC is unclear.
Contribution
The authors of this retrospective cohort study analyzed Medicaid and Medicare data to examine the survival of patients with advanced UC who pursued elective colectomy compared with those receiving medical therapy.
Caution
Some of the sensitivity and subgroup analyses had reduced statistical power. change in the effect estimate were retained in the final model. The test of the proportional hazards assumption evaluated the interaction of treatment and the natural logarithm of follow-up time. Comorbidity-standardized survival proportion and cumulative incidence were calculated using inverse probability weighting (33) (Supplement).
A sensitivity analysis was conducted that excluded 196 elective colectomy patients (as well as their matched medically treated patients) who first met the criteria for advanced disease on the day of their surgery. In a secondary sensitivity analysis, we excluded these patients along with an additional 160 elective colectomy patients (and their medically treated matches) who had no identifiable IBD medications in the 180 days before the start of follow-up in the Medicare and Medicaid data (Appendix Table 2 , available at www .annals.org). Additional sensitivity analyses were stratified by treatment before the start of follow-up.
To assess the robustness of our findings, we reran the main analysis and the primary sensitivity analysis 20 times with matched medical therapy patients who were randomly resampled. All statistical analyses were performed using SAS, version 9.3 (SAS Institute).
Although the study sample size was limited by available data, a priori power calculations (assuming ␣ = 0.05) estimated that with 1:1 matching of medical therapy patients and elective surgery patients and an assumed relative survival of 0.5 in the medical therapy group, we would need approximately 350 patients in each group to reject the null hypothesis of equal survival with 80% power. 
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RESULTS
We identified 32 833 patients with advanced UC as defined by our inclusion criteria ( Figure 1 ). Of these, 847 had elective colectomy. Seventeen of these patients could not be matched because of prior medication use and duration of advanced disease and were excluded from our analysis. Thus, 830 elective surgery patients were included in our main analysis. Table 1 and Appendix Table 2 describe the demographic characteristics for the overall and sensitivity analyses, respectively.
The mortality rates associated with elective colectomy and medical therapy in the overall cohort were 34 and 54 deaths per 1000 person-years, respectively ( Table 2) . Elective colectomy was associated with improved survival compared with medical therapy in unadjusted analyses (HR, 0.70 [95% CI, 0.54 to 0.90]) (Table 2), although neither the primary nor the secondary sensitivity analysis showed significantly greater survival in patients pursuing elective surgery. When the analysis was limited to the patients who were removed in the primary sensitivity analysis (that is, the 196 surgery patients who entered the advanced disease cohort on the day of elective surgery and their matches), patients pursuing elective colectomy had greater survival (HR, 0.30 [CI, 0.16 to 0.56]).
The number of non-IBD medications and emergency department visits in the prior 180 days and calendar year of cohort entry did not meet our definition of confounders. Adjustment for comorbid conditions increased the strength of association between treatment and mortality in the main analysis (HR, 0.67 [CI, 0.52 to 0.87]) and the sensitivity analysis ( Table 2) . Divergence in the survival proportion started at 180 days postoperatively and continued into follow-up (Table 3 and Figure 2) .
To ensure the robustness of our analysis, we reran the models in 20 different randomly selected matched cohorts. The mean HR differed from the reported results by less than 2% in each analysis evaluated, and the maximum difference in any individual analysis was 7.24%.
Because prior studies have shown an age-based survival benefit of elective colectomy (24), we also examined age as an effect modifier. The interaction of age 65 years or older (vs. <65 years) with treatment was not significant (P = 0.27) despite a survival benefit for surgery in patients with UC in this age group (HR adjusted for comorbid conditions, 0.60 [CI, 0.45 to 0.80]). However, the interaction of age 50 years or older (vs. * Not all patients were exposed to immunosuppressants or corticosteroids in the 180 d before follow-up; some were exposed to mesalamine or had no medication exposure (and were removed in sensitivity analysis). † Medical therapy patients were weighted in the analysis according to the number of patients in each matched group. The numbers reported here are not weighted and do not reflect the balance achieved with the matching. ‡ Use of these data was governed by a data use agreement with the Centers for Medicare & Medicaid Services, which prohibits displaying any cell size <11. § Includes hospitalization with primary diagnosis of UC; ≥2 oral corticosteroid prescriptions within 90 d; or any prescription for immunosuppressant therapy, including cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, and/or infliximab. P value for difference between cohorts was <0.001.
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ORIGINAL RESEARCH <50 years) with treatment was significant (P = 0.032). Therefore, post hoc analysis was performed examining age younger than 50 years and age 50 years or older, with adjustment for comorbid conditions. In patients younger than 50 years, survival with elective colectomy and medical therapy did not differ significantly. Table 2) . Analyses were performed that were limited to patients treated with immunosuppressant therapy only (azathioprine-6-mercaptopurine, infliximab, or cyclosporine-tacrolimus) or corticosteroids only in the 6 months before the start of follow-up. Survival did not differ between the medical therapy and surgically treated patients in these subgroups, although these analyses were underpowered ( Table 2) . Potential causes of increased mortality in medical therapy patients were also examined. During follow-up, those pur- 
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suing colectomy were more likely to have infections and use narcotics but less likely to use corticosteroids after the first several months (Appendix Table 3 , available at www.annals.org).
DISCUSSION
We observed that among Medicare and Medicaid beneficiaries with advanced UC, specifically among those aged 50 years or older, elective colectomy is associated with significantly improved relative survival compared with medical therapy. To our knowledge, this is the first population-based study to examine relative survival with elective colectomy versus medical therapy for UC in the United States and the first such study to adjust for medication use before surgery. Two prior population-based studies from Europe observed similar improved relative survival in patients with UC pursuing elective colectomy compared with those hospitalized for their disease (19, 24) . However, neither study was able to adjust for medication use before surgery, which allowed for confounding by indication if the choice not to pursue surgery was linked to risk for death through a factor other than the treatment decision. To address this, we matched our medical therapy and surgery cohorts on key factors, including age, definition of advanced disease, duration of advanced disease, and recent medical therapy, and further adjusted for concomitant comorbid conditions. We also performed additional sensitivity analyses to address this concern. Specifically, in our primary sensitivity analysis, we removed a group of elective colectomy patients who were (by our definition) relatively well and were labeled as having advanced disease solely because they were hospitalized for surgery; their matched medical therapy patients comprised those with UC severe enough to also warrant hospitalization but not elective surgery ( Table 2) . Not surprisingly, a large survival benefit was associated with surgery in this excluded cohort. However, even after exclusion of these patients, surgery was associated with a survival benefit in older patients.
Prior work has indicated a survival benefit of elective colectomy in UC starting at age 50 years (24) . In our study, we performed a post hoc analysis that also confirmed a survival benefit in patients aged 50 years or older. Of note, we also found a survival benefit with surgery in patients with UC aged 65 years or older, although the interaction of age (<65 vs. ≥65 years) with treatment (adjusted for comorbid conditions) was nonsignificant.
We did not find a survival benefit associated with elective colectomy in patients younger than 50 years. These results should be interpreted with caution, given that these analyses were performed post hoc and involved a smaller sample size and low absolute number of deaths (78 total). We found that the proportion of medical therapy patients receiving immunosuppressants was similar in those younger than 50 years and those aged 50 years or older (data not shown). None- * Figure 2 shows a graphical representation of these data. † Estimates for medical therapy patients were standardized to the surgery group by using the Romano/Charlson-Elixhauser comorbidity index. ‡ Use of these data was governed by a data use agreement with the Centers for Medicare & Medicaid Services, which prohibits displaying any cell size <11. Cumulative incidence is shown by solid lines, and 95% CIs are indicated by dashed lines. Data used to generate the graph are provided in Table 3 .
Mortality Associated With Medical Therapy Versus Elective Colectomy in UC ORIGINAL RESEARCH theless, because complications from medical therapy are less common in young patients (34) and death from any cause is relatively rare before age 50 years, even the small absolute risk for perioperative death represents a larger relative risk in this population. However, in younger patients with UC that is refractory to medication, elective surgery can be beneficial in reducing morbidity and mortality; thus, our findings should not be interpreted as indicating that surgery should be universally avoided in this younger population. When only patients receiving immunosuppressant therapy or corticosteroids before follow-up were examined, survival did not statistically significantly differ between medical therapy and surgery. These analyses were underpowered but suggest important concepts. In patients treated only with corticosteroids, particularly those older than 50 years, the HR for mortality was similar to that in prior studies that found increased mortality associated with corticosteroids (4, 35) . Our data also point to similar survival with medical therapy or surgery in patients in stable remission who are receiving immunosuppressant therapy. Alternatively, the finding of a survival benefit for elective colectomy among patients older than 50 years but not in the subgroup treated with immunosuppressant therapy could have been due to an unmeasured comorbid condition that precluded use of these immunosuppressant therapies or surgery and increased the risk for death. The proportion of patients with advanced disease who were receiving longterm immunosuppressant therapy was relatively small, which may be due to patients having disease refractory to these therapies, misunderstanding about the risks of continued active disease, or patients' preferences to avoid long-term immunosuppression. The comparative effectiveness of different medical treatment strategies, particularly in elderly adults, should be a focus of further research.
The findings of this study have important implications for both patients and providers with regard to informed decision making about UC. Traditionally, providers have assumed that patients with UC desire to avoid colectomy given resulting changes in quality of life. Discussions of surgical options for UC are therefore often not initiated or are initiated only when all other medical therapies have failed, even though the literature suggests improved quality of life after surgery (21, 36 -39) . Recent work has shown that patients with UC are willing to accept surgery to avoid potentially lethal serious adverse effects of long-term immunosuppressant therapies, especially if these therapies are not completely effective in maintaining a durable remission (25) . Our finding of a survival advantage associated with elective colectomy in patients aged 50 years or older underlines the need for earlier and more informed discussions about surgical options for UC to improve shared decision making. Specifically, this finding emphasizes that intermittent corticosteroid use or advanced UC that is incompletely controlled may be associated with an increased risk for death.
Our study has potential limitations. Medicare and Medicaid data are collected for administrative purposes, and the diagnosis of UC has not been validated. In our study, patients with UC had an average of 13.6 clinical encounters (median, 6) with an ICD-9 -coded diagnosis of UC. Our inclusion criteria also required patients to have concomitant prescriptions for corticosteroids, immunosuppressants, or both or to have a primary hospitalization for UC, thus limiting potential misclassification. Medicare and Medicaid data do not explicitly label surgery as emergent or elective. However, our definition of elective surgery produced postoperative mortality rates similar to those in other national data sets that examined mortality in Medicare and Medicaid beneficiaries who had surgery that was defined as elective (16) , which lends support to our methods and findings.
Our source populations differed by time frame. To account for this, we matched by age and Medicaid status and tested calendar year of cohort entry as a potential confounder and effect modifier, although we found no evidence of confounding or modification by time frame.
Medicare and Medicaid are the primary insurance for 18% of the U.S. population, so they cover an overall large population of patients with UC. However, findings among Medicare and Medicaid beneficiaries may not be generalizable to the broader U.S. population. For example, patients in our study who were younger than 65 years qualified for Medicare because of disability, although we could not determine whether this was a direct result of their UC. Of note, however, our analysis was limited to comparison within the Medicare and Medicaid population itself; thus, although our absolute mortality rates may differ from those of other populations, our relative mortality rates should not. The similarity of our results to those of 2 population-based studies from Europe (19, 24) suggests that these results are probably generalizable to the broader U.S. population.
We did not examine cause of death because it is subject to significant misclassification in administrative databases (40, 41). We did not find differences in infections or narcotic use that would explain the difference in mortality rates. Corticosteroid use after the first few months was more common in the medically treated patients. We were unable to adjust for smoking because it is not a coded diagnosis in the data set. Evidence shows that tobacco use may alleviate UC symptoms, and one could therefore speculate that smokers may be less likely to pursue surgery but more likely to die of smoking-related diseases (42). We excluded patients with concomitant diagnoses of asthma or chronic obstructive pulmonary disease, both of which are associated with tobacco use. We also adjusted for the Romano/Charlson-Elixhauser comorbidity index, which contains several smoking-related comorbid conditions (32) .
In conclusion, we found that in Medicare and Medicaid beneficiaries with UC requiring hospitalization, multiple corticosteroid prescriptions, or immunosuppressant therapy, long-term survival after elective surgery is greater than with long-term medical therapy. Post hoc analysis suggests that this survival benefit was ORIGINAL RESEARCH Mortality Associated With Medical Therapy Versus Elective Colectomy in UC most evident in patients aged 50 years or older, although it was not evident in the subgroup of older patients treated with immunosuppressants for their advanced UC. These findings warrant discussion with patients when one is weighing the risks and benefits of different medical therapies and total colectomy.
